{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:00:19Z","timestamp":1778626819250,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s13277-014-1607-8","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T01:06:16Z","timestamp":1389229576000},"page":"4637-4644","source":"Crossref","is-referenced-by-count":14,"title":["Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells"],"prefix":"10.1007","volume":"35","author":[{"given":"Zhi-hua","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Te","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-tao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"1607_CR1","first-page":"1277","volume":"23","author":"T Liu","year":"2010","unstructured":"Liu T, Cheng W, Lai D, Huang Y, Guo L. Characterization of primary ovarian cancer cells in different culture systems. Oncol Rep. 2010;23:1277\u201384.","journal-title":"Oncol Rep"},{"key":"1607_CR2","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","volume":"68","author":"S Zhang","year":"2008","unstructured":"Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311\u201320.","journal-title":"Cancer Res"},{"key":"1607_CR3","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.febslet.2013.03.023","volume":"587","author":"W Qin","year":"2013","unstructured":"Qin W, Ren Q, Liu T, Huang Y, Wang J. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 2013;587:1434\u20139.","journal-title":"FEBS Lett"},{"key":"1607_CR4","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1742-4658.2012.08589.x","volume":"279","author":"W Cheng","year":"2012","unstructured":"Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279:2047\u201359.","journal-title":"FEBS J"},{"key":"1607_CR5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3892\/ijo.2013.1806","volume":"42","author":"DR Maddirela","year":"2013","unstructured":"Maddirela DR, Kesanakurti D, Gujrati M, Rao JS. MMP-2 suppression abrogates irradiation-induced microtubule formation in endothelial cells by inhibiting \u03b1v\u03b23-mediated SDF-1\/CXCR4 signaling. Int J Oncol. 2013;42:1279\u201388.","journal-title":"Int J Oncol"},{"key":"1607_CR6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2559.2011.04139.x","volume":"61","author":"MF Fanelli","year":"2012","unstructured":"Fanelli MF, Chinen LT, Begnami MD, Costa Jr WL, Fregnami JH, Soares FA, et al. The influence of transforming growth factor-alpha, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 2012;61:153\u201361.","journal-title":"Histopathology"},{"key":"1607_CR7","first-page":"491985","volume":"2009","author":"EL Hsu","year":"2009","unstructured":"Hsu EL, Chen N, Westbrook A, Wang F, Zhang R, Taylor RT, et al. Modulation of CXCR4, CXCL12, and tumor cell invasion potential in vitro by phytochemicals. J Oncol. 2009;2009:491985.","journal-title":"J Oncol"},{"key":"1607_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/carcin\/bgl129","volume":"28","author":"P Maroni","year":"2007","unstructured":"Maroni P, Bendinelli P, Matteucci E, Desiderio MA. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis. 2007;28:267\u201379.","journal-title":"Carcinogenesis"},{"key":"1607_CR9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/IGC.0b013e31821d2543","volume":"21","author":"J Wang","year":"2011","unstructured":"Wang J, Cai J, Han F, Yang C, Tong Q, Cao T, et al. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway. Int J Gynecol Cancer. 2011;21:981\u20137.","journal-title":"Int J Gynecol Cancer"},{"key":"1607_CR10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/01.cej.0000236259.88146.a4","volume":"16","author":"Y Yuecheng","year":"2007","unstructured":"Yuecheng Y, Xiaoyan X. Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2. Eur J Cancer Prev. 2007;16:430\u20135.","journal-title":"Eur J Cancer Prev"},{"key":"1607_CR11","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3109\/13880209.2012.664151","volume":"50","author":"SH Baek","year":"2012","unstructured":"Baek SH, Kim SM, Nam D, Lee JH, Ahn KS, Choi SH, et al. Antimetastatic effect of nobiletin through the down-regulation of cxc chemokine receptor type 4 and matrix metallopeptidase-9. Pharm Biol. 2012;50:1210\u20138.","journal-title":"Pharm Biol"},{"key":"1607_CR12","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1182\/blood-2002-12-3893","volume":"101","author":"KW Christopherson 2nd","year":"2003","unstructured":"Christopherson 2nd KW, Cooper S, Broxmeyer HE. Cell surface peptidase CD26\/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood. 2003;101:4680\u20136.","journal-title":"Blood"},{"key":"1607_CR13","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1172\/JCI66553","volume":"123","author":"Y Chen","year":"2013","unstructured":"Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013;123:2395\u2013407.","journal-title":"J Clin Invest"},{"key":"1607_CR14","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-10-3143","volume":"71","author":"E Righi","year":"2011","unstructured":"Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, et al. CXCL12\/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011;71:5522\u201334.","journal-title":"Cancer Res"},{"key":"1607_CR15","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1593\/neo.111076","volume":"13","author":"P Ray","year":"2012","unstructured":"Ray P, Lewin SA, Mihalko LA, Schmidt BT, Luker KE, Luker GD. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. Neoplasia. 2012;13:1152\u201361.","journal-title":"Neoplasia"},{"key":"1607_CR16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/mc.21913","volume":"52","author":"JM Hall","year":"2012","unstructured":"Hall JM, Korach KS. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis. Mol Carcinog. 2012;52:715\u201325.","journal-title":"Mol Carcinog"},{"key":"1607_CR17","doi-asserted-by":"crossref","first-page":"e51500","DOI":"10.1371\/journal.pone.0051500","volume":"8","author":"E Salomonnson","year":"2013","unstructured":"Salomonnson E, Stacer AC, Ehrlich A, Luker KE, Luker GD. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy. PLoS One. 2013;8:e51500.","journal-title":"PLoS One"},{"key":"1607_CR18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1744-8069-8-71","volume":"8","author":"L Deng","year":"2012","unstructured":"Deng L, Guindon J, Vemuri VK, Thakur GA, White FA, Makriyannis A, et al. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB(2) receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain. 2012;8:71.","journal-title":"Mol Pain"},{"key":"1607_CR19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","volume":"110","author":"G Ramesh","year":"2002","unstructured":"Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110:835\u201342.","journal-title":"J Clin Invest"},{"key":"1607_CR20","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1158\/1078-0432.CCR-04-2117","volume":"11","author":"G Li","year":"2005","unstructured":"Li G, Tian L, Hou JM, Ding ZY, He QM, Feng P, et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors. Clin Cancer Res. 2005;11:4217\u201324.","journal-title":"Clin Cancer Res"},{"key":"1607_CR21","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.gt.3302756","volume":"13","author":"R Zhang","year":"2006","unstructured":"Zhang R, Tian L, Chen LJ, Xiao F, Hou JM, Zhao X, et al. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther. 2006;13:1263\u201371.","journal-title":"Gene Ther"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-014-1607-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1607-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T22:21:35Z","timestamp":1565043695000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-014-1607-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["1607"],"URL":"https:\/\/doi.org\/10.1007\/s13277-014-1607-8","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]}}}